Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. ELV

Go back to Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c

Halozyme Reports Second Quarter 2015 Financial Results

August 10, 2015 4:05 PM EDT

SAN DIEGO, Aug. 10, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the second quarter ended June 30, 2015. Financial highlights include revenues of $43.4 million and net income of $3.0 million, or $0.02 per share, compared to revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share, for the second quarter of 2014.  

"Our performance in the quarter continued to demonstrate the strength of our two-pillar strategy," said Dr. Helen Torley, president and CEO. "In the ENHANZE pillar, we signed our... More